Psyence Biomedical Ltd. - Common Shares (PBM) analyst actions
Rating and price-target actions on PBM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PBM overview →
3 measured PBM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder | Press release | +3.85% | +5.37% | |
| Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care | Press release | -11.82% | -15.16% | |
| Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care | Press release | -1.61% | -5.03% |
Keep exploring
More PBM: earnings → · SEC filings → · PBM overview →